Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity

•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2021-01, Vol.90, p.107193, Article 107193
Hauptverfasser: Alomar, Suliman Y., M. Barakat, Bassant, Eldosoky, Mohamed, Atef, Hoda, Mohamed, Abdelaty Shawky, Elhawary, Reda, El-Shafey, Mohamed, Youssef, Amal M., Elkazaz, Amany Y., Gabr, Attia M., Elaskary, Abdelhakeem A., Salih, Mohamed A.K., Alolayan, Sultan Othman, Zaitone, Sawsan A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 107193
container_title International immunopharmacology
container_volume 90
creator Alomar, Suliman Y.
M. Barakat, Bassant
Eldosoky, Mohamed
Atef, Hoda
Mohamed, Abdelaty Shawky
Elhawary, Reda
El-Shafey, Mohamed
Youssef, Amal M.
Elkazaz, Amany Y.
Gabr, Attia M.
Elaskary, Abdelhakeem A.
Salih, Mohamed A.K.
Alolayan, Sultan Othman
Zaitone, Sawsan A.
description •Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level. Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.
doi_str_mv 10.1016/j.intimp.2020.107193
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2491613262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576920336602</els_id><sourcerecordid>2491613262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</originalsourceid><addsrcrecordid>eNp9kc2OFCEUhYnROOPoGxhD4rp6oKCA2pjoZPxJJtGFrgkFt5SeKiiB6nS_jk8qnRpn6YZ7c_Kde4GD0GtKdpRQcb3f-VD8vOxa0p4lSXv2BF1SJVVDJeme1r4Tsumk6C_Qi5z3hFSd0-fogrGWC9XKS_TnW4oFbPEHwDCOtcNxxDOUMabZBxwDTqZg580AxVuc6hniYsqvE_bhEKcDZJzXZUmQs690dZc4Tc3k76HSFpYSE-bXYbUTmIRHY6vQ3OMPGI6PLhMc_jmtxcym1IscrS-xxKOv9fQSPRvNlOHVQ71CPz7efr_53Nx9_fTl5v1dY3knSjPYVjCmZN8y5aAfeso5l8p0ijhlOzY4yQdBwTklhOnHnhrSUeXUSLpBSMKu0Ntt7pLi7xVy0fu4plBX6pb3VFDWirZSfKNsijknGPWS_GzSSVOiz8Hovd6C0edg9BZMtb15GL4OM7hH078kKvBuA6A-8eAh6Ww9BAvO118s2kX__w1_AdkxpHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491613262</pqid></control><display><type>article</type><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</creator><creatorcontrib>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</creatorcontrib><description>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level. Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&amp;4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2020.107193</identifier><identifier>PMID: 33246827</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antioxidants ; Complications ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Experimental - chemically induced ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - metabolism ; Diabetic retinopathy ; Diabetic Retinopathy - etiology ; Diabetic Retinopathy - metabolism ; Diabetic Retinopathy - pathology ; Diabetic Retinopathy - prevention &amp; control ; Excitotoxicity ; Gene expression ; Glutamate excitotoxicity ; Glutamic Acid - metabolism ; Growth factors ; Hypoglycemic Agents - pharmacology ; Inflammation ; Insulin ; Male ; Malondialdehyde ; Metformin ; Metformin - pharmacology ; Microvasculature ; NF-kappa B - genetics ; NF-kappa B - metabolism ; NF-κB protein ; Oxidative stress ; Oxidative Stress - drug effects ; Rat diabetic retinopathy ; Rats ; Rats, Wistar ; Receptors ; Retina ; Retina - drug effects ; Retina - metabolism ; Retina - pathology ; Retinopathy ; Rodents ; Signal Transduction ; Streptozocin ; TLR4 protein ; TLR4/NFkB ; Toll-Like Receptor 4 - genetics ; Toll-Like Receptor 4 - metabolism ; Toll-like receptors ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>International immunopharmacology, 2021-01, Vol.90, p.107193, Article 107193</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Jan 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</citedby><cites>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</cites><orcidid>0000-0002-9688-7683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2020.107193$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33246827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alomar, Suliman Y.</creatorcontrib><creatorcontrib>M. Barakat, Bassant</creatorcontrib><creatorcontrib>Eldosoky, Mohamed</creatorcontrib><creatorcontrib>Atef, Hoda</creatorcontrib><creatorcontrib>Mohamed, Abdelaty Shawky</creatorcontrib><creatorcontrib>Elhawary, Reda</creatorcontrib><creatorcontrib>El-Shafey, Mohamed</creatorcontrib><creatorcontrib>Youssef, Amal M.</creatorcontrib><creatorcontrib>Elkazaz, Amany Y.</creatorcontrib><creatorcontrib>Gabr, Attia M.</creatorcontrib><creatorcontrib>Elaskary, Abdelhakeem A.</creatorcontrib><creatorcontrib>Salih, Mohamed A.K.</creatorcontrib><creatorcontrib>Alolayan, Sultan Othman</creatorcontrib><creatorcontrib>Zaitone, Sawsan A.</creatorcontrib><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level. Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&amp;4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</description><subject>Animals</subject><subject>Antioxidants</subject><subject>Complications</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Experimental - chemically induced</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - etiology</subject><subject>Diabetic Retinopathy - metabolism</subject><subject>Diabetic Retinopathy - pathology</subject><subject>Diabetic Retinopathy - prevention &amp; control</subject><subject>Excitotoxicity</subject><subject>Gene expression</subject><subject>Glutamate excitotoxicity</subject><subject>Glutamic Acid - metabolism</subject><subject>Growth factors</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Male</subject><subject>Malondialdehyde</subject><subject>Metformin</subject><subject>Metformin - pharmacology</subject><subject>Microvasculature</subject><subject>NF-kappa B - genetics</subject><subject>NF-kappa B - metabolism</subject><subject>NF-κB protein</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Rat diabetic retinopathy</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors</subject><subject>Retina</subject><subject>Retina - drug effects</subject><subject>Retina - metabolism</subject><subject>Retina - pathology</subject><subject>Retinopathy</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>Streptozocin</subject><subject>TLR4 protein</subject><subject>TLR4/NFkB</subject><subject>Toll-Like Receptor 4 - genetics</subject><subject>Toll-Like Receptor 4 - metabolism</subject><subject>Toll-like receptors</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2OFCEUhYnROOPoGxhD4rp6oKCA2pjoZPxJJtGFrgkFt5SeKiiB6nS_jk8qnRpn6YZ7c_Kde4GD0GtKdpRQcb3f-VD8vOxa0p4lSXv2BF1SJVVDJeme1r4Tsumk6C_Qi5z3hFSd0-fogrGWC9XKS_TnW4oFbPEHwDCOtcNxxDOUMabZBxwDTqZg580AxVuc6hniYsqvE_bhEKcDZJzXZUmQs690dZc4Tc3k76HSFpYSE-bXYbUTmIRHY6vQ3OMPGI6PLhMc_jmtxcym1IscrS-xxKOv9fQSPRvNlOHVQ71CPz7efr_53Nx9_fTl5v1dY3knSjPYVjCmZN8y5aAfeso5l8p0ijhlOzY4yQdBwTklhOnHnhrSUeXUSLpBSMKu0Ntt7pLi7xVy0fu4plBX6pb3VFDWirZSfKNsijknGPWS_GzSSVOiz8Hovd6C0edg9BZMtb15GL4OM7hH078kKvBuA6A-8eAh6Ww9BAvO118s2kX__w1_AdkxpHc</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Alomar, Suliman Y.</creator><creator>M. Barakat, Bassant</creator><creator>Eldosoky, Mohamed</creator><creator>Atef, Hoda</creator><creator>Mohamed, Abdelaty Shawky</creator><creator>Elhawary, Reda</creator><creator>El-Shafey, Mohamed</creator><creator>Youssef, Amal M.</creator><creator>Elkazaz, Amany Y.</creator><creator>Gabr, Attia M.</creator><creator>Elaskary, Abdelhakeem A.</creator><creator>Salih, Mohamed A.K.</creator><creator>Alolayan, Sultan Othman</creator><creator>Zaitone, Sawsan A.</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-9688-7683</orcidid></search><sort><creationdate>202101</creationdate><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><author>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antioxidants</topic><topic>Complications</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Experimental - chemically induced</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - etiology</topic><topic>Diabetic Retinopathy - metabolism</topic><topic>Diabetic Retinopathy - pathology</topic><topic>Diabetic Retinopathy - prevention &amp; control</topic><topic>Excitotoxicity</topic><topic>Gene expression</topic><topic>Glutamate excitotoxicity</topic><topic>Glutamic Acid - metabolism</topic><topic>Growth factors</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Male</topic><topic>Malondialdehyde</topic><topic>Metformin</topic><topic>Metformin - pharmacology</topic><topic>Microvasculature</topic><topic>NF-kappa B - genetics</topic><topic>NF-kappa B - metabolism</topic><topic>NF-κB protein</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Rat diabetic retinopathy</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors</topic><topic>Retina</topic><topic>Retina - drug effects</topic><topic>Retina - metabolism</topic><topic>Retina - pathology</topic><topic>Retinopathy</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>Streptozocin</topic><topic>TLR4 protein</topic><topic>TLR4/NFkB</topic><topic>Toll-Like Receptor 4 - genetics</topic><topic>Toll-Like Receptor 4 - metabolism</topic><topic>Toll-like receptors</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alomar, Suliman Y.</creatorcontrib><creatorcontrib>M. Barakat, Bassant</creatorcontrib><creatorcontrib>Eldosoky, Mohamed</creatorcontrib><creatorcontrib>Atef, Hoda</creatorcontrib><creatorcontrib>Mohamed, Abdelaty Shawky</creatorcontrib><creatorcontrib>Elhawary, Reda</creatorcontrib><creatorcontrib>El-Shafey, Mohamed</creatorcontrib><creatorcontrib>Youssef, Amal M.</creatorcontrib><creatorcontrib>Elkazaz, Amany Y.</creatorcontrib><creatorcontrib>Gabr, Attia M.</creatorcontrib><creatorcontrib>Elaskary, Abdelhakeem A.</creatorcontrib><creatorcontrib>Salih, Mohamed A.K.</creatorcontrib><creatorcontrib>Alolayan, Sultan Othman</creatorcontrib><creatorcontrib>Zaitone, Sawsan A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alomar, Suliman Y.</au><au>M. Barakat, Bassant</au><au>Eldosoky, Mohamed</au><au>Atef, Hoda</au><au>Mohamed, Abdelaty Shawky</au><au>Elhawary, Reda</au><au>El-Shafey, Mohamed</au><au>Youssef, Amal M.</au><au>Elkazaz, Amany Y.</au><au>Gabr, Attia M.</au><au>Elaskary, Abdelhakeem A.</au><au>Salih, Mohamed A.K.</au><au>Alolayan, Sultan Othman</au><au>Zaitone, Sawsan A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>90</volume><spage>107193</spage><pages>107193-</pages><artnum>107193</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level. Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&amp;4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33246827</pmid><doi>10.1016/j.intimp.2020.107193</doi><orcidid>https://orcid.org/0000-0002-9688-7683</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2021-01, Vol.90, p.107193, Article 107193
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_journals_2491613262
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Antioxidants
Complications
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Experimental - chemically induced
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - metabolism
Diabetic retinopathy
Diabetic Retinopathy - etiology
Diabetic Retinopathy - metabolism
Diabetic Retinopathy - pathology
Diabetic Retinopathy - prevention & control
Excitotoxicity
Gene expression
Glutamate excitotoxicity
Glutamic Acid - metabolism
Growth factors
Hypoglycemic Agents - pharmacology
Inflammation
Insulin
Male
Malondialdehyde
Metformin
Metformin - pharmacology
Microvasculature
NF-kappa B - genetics
NF-kappa B - metabolism
NF-κB protein
Oxidative stress
Oxidative Stress - drug effects
Rat diabetic retinopathy
Rats
Rats, Wistar
Receptors
Retina
Retina - drug effects
Retina - metabolism
Retina - pathology
Retinopathy
Rodents
Signal Transduction
Streptozocin
TLR4 protein
TLR4/NFkB
Toll-Like Receptor 4 - genetics
Toll-Like Receptor 4 - metabolism
Toll-like receptors
Tumor Necrosis Factor-alpha - genetics
Tumor Necrosis Factor-alpha - metabolism
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - metabolism
title Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A54%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20metformin%20on%20rat%20diabetic%20retinopathy%20involves%20suppression%20of%20toll-like%20receptor%204/nuclear%20factor-k%20B%20expression%20and%20glutamate%20excitotoxicity&rft.jtitle=International%20immunopharmacology&rft.au=Alomar,%20Suliman%20Y.&rft.date=2021-01&rft.volume=90&rft.spage=107193&rft.pages=107193-&rft.artnum=107193&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2020.107193&rft_dat=%3Cproquest_cross%3E2491613262%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2491613262&rft_id=info:pmid/33246827&rft_els_id=S1567576920336602&rfr_iscdi=true